Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 4/20 | 0.41 |
| ▸ | TPSD1 | Q9BZJ3 | 4/20 | 0.41 |
| ▸ | TPSG1 | Q9NRR2 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9363422 | 0.92 | TPSAB1 (0.41) | TPSAB1TPSD1TPSG1L3MBTL1HRH3 | |
| SCHEMBL5623295 | 0.82 | L3MBTL1 (0.54) | TPSAB1TPSD1TPSG1L3MBTL1HRH3 | |
| SCHEMBL31512292 | 0.81 | L3MBTL1 (0.51) | TPSAB1TPSD1TPSG1L3MBTL1HRH3 | |
| SCHEMBL22080031 | 0.80 | TP53 (0.42) | TPSAB1TPSD1TPSG1HRH3KMT2A | |
| SCHEMBL5623233 | 0.79 | TPSAB1 (0.45) | TPSAB1TPSD1TPSG1MAPTKMT2A | |
| SCHEMBL12520131 | 0.79 | TPSAB1 (0.45) | TPSAB1TPSD1TPSG1MAPTKMT2A | |
| SCHEMBL18505995 | 0.79 | TSHR (0.46) | L3MBTL1HRH3TSHRUSP2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL22032094 | 0.79 | TP53 (0.41) | TPSAB1TPSD1TPSG1HRH3KMT2A | |
| SCHEMBL12162946 | 0.77 | HRH3 (0.51) | TPSAB1TPSD1TPSG1L3MBTL1HRH3 | |
| SCHEMBL29703400 | 0.76 | TPSAB1 (0.45) | TPSAB1TPSD1TPSG1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12049477-B2 | Azithromycin derivatives with epithelial barrier enhancement properties | EPIENDO PHARMACEUTICALS EHF. (IS) | 2024-07-30 | — | — | US | claimed |
| US-20220106349-A1 | Compounds | EPIENDO PHARMACEUTICALS EHF (IS) | 2022-04-07 | — | — | US | claimed |
| WO-2026041802-A1 | AZITHROMYCIN DERIVATIVES FOR USE IN THE TREATMENT OF INFECTIONS | EPIENDO PHARMACEUTICALS EHF (IS) | 2026-02-26 | — | — | WO | disclosed |
| EP-4683641-A1 | AZITHROMYCIN DERIVATIVES FOR USE IN THE TREATMENT OF EOSINOPHIL-RELATED DISEASES | EpiEndo Pharmaceuticals ehf. (IS) | 2026-01-28 | — | — | EP | disclosed |
| WO-2024194494-A1 | AZITHROMYCIN DERIVATIVES FOR USE IN THE TREATMENT OF EOSINOPHIL-RELATED DISEASES | EPIENDO PHARMACEUTICALS EHF (IS) | 2024-09-26 | — | — | WO | disclosed |
| US-12049477-B2 | Azithromycin derivatives with epithelial barrier enhancement properties | EPIENDO PHARMACEUTICALS EHF. (IS) | 2024-07-30 | — | — | US | disclosed |
| US-20220106349-A1 | Compounds | EPIENDO PHARMACEUTICALS EHF (IS) | 2022-04-07 | — | — | US | disclosed |
| US-11236120-B2 | Azithromycin derivatives with epithelial barrier enhancement properties | EPIENDO PHARMACEUTICALS EHF (IS) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106349-A1 | Compounds | CFTR, AQP1, CTSA | TPSAB1 1869/4885TPSD1 3323/4885TPSG1 3123/4885 |
| US-12049477-B2 | Azithromycin derivatives with epithelial barrier enhancement properties | CFTR, AQP1, CTSA | TPSAB1 888/4885TPSD1 1801/4885TPSG1 2685/4885 |
| US-11236120-B2 | Azithromycin derivatives with epithelial barrier enhancement properties | CFTR, AQP1, CTSA | TPSAB1 888/4885TPSD1 1801/4885TPSG1 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.